MedTrace Logo

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

NCT04129099 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-05-28

No results posted yet for this study

Summary

The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 18 subjects to receive GC022F therapy.

Conditions

Interventions

BIOLOGICAL

GC022F

GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10\^4 to 1.5×10\^5 CAR+T/Kg.

Sponsors & Collaborators

  • Gracell Biotechnology Ltd.

    collaborator OTHER

  • Beijing Lu Daopei Hospital

    collaborator OTHER

  • Hebei Yanda Ludaopei Hospital

    lead OTHER

Principal Investigators

  • Junfang Yang, Bachelor · Hebei Yanda Ludaopei Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-22
Primary Completion
2020-09-30
Completion
2022-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04129099 on ClinicalTrials.gov